Efficacy of Methylphenidate for Adults with Attention-Deficit Hyperactivity Disorder

Background: The efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder (ADHD) shows wide between-study variability, which yields heterogeneous results in meta-analysis. The reasons for this variability have not been comprehensively investigated.Objectives: To determine the influence of treatment-related covariates of methylphenidate for adults with ADHD by means of meta-analysis. Clinical and methodological moderators and clinical trial reporting quality were also collected to control for their potential confounding effect.Methods: We searched for randomized, placebo-controlled clinical trials investigating the efficacy of methylphenidate for adults with ADHD. The study outcome was the efficacy of methylphenidate for reducing ADHD symptom severity. Treatment-related covariates included dose, type of drug-release formulation (formulations with a continuous drug release vs those with a non-continuous drug release), dose regimen (fixed vs flexible) and treatment length. Clinical (presence of co-morbid substance use disorders [SUD]) and methodological (design and rater) covariates were also collected, in addition to clinical trial reporting quality. The standardized mean difference (SMD) was calculated for each study. The analysis of the influence of methylphenidate effect modifiers was performed by means of random-effects meta-regression.Results: Eighteen studies were included. Dose, type of formulation and SUD appeared to modify the efficacy of methylphenidate in the bivariate analysis. These variables were included in a multivariate meta-regression, which showed that methylphenidate, at an average dose of 57.4 mg/day, delivered by means of non-continuous-release formulations, had a moderate effect on ADHD symptoms compared with placebo (SMD 0.57–0.58). A dose-response relationship was found, indicating that efficacy could be increased by SMD 0.11–0.12 for every 10 mg increment of methylphenidate. Continuous-release formulations and co-morbid SUD appeared to reduce the efficacy of methylphenidate. Nevertheless, the effect of treatment formulation may have been confounded by co-morbid SUD, since all studies using this continuous-release formulation were conducted in dual ADHD-SUD patients. No residual heterogeneity was found.Conclusions: This study shows that methylphenidate improves ADHD symptoms in adults in a dose-dependent fashion. The efficacy of methylphenidate appears to be reduced in patients with co-morbid SUD. It is unclear whether methylphenidate efficacy is influenced by the type of formulation, because the effect of this covariate is confounded by that of co-morbid SUD.

[1]  S. Chinn.  A simple method for converting an odds ratio to effect size for use in meta-analysis. , 2000, Statistics in medicine.

[2]  T. B. Üstün,et al.  The Prevalence and Effects of Adult Attention Deficit/Hyperactivity Disorder on Work Performance in a Nationally Representative Sample of Workers , 2005, Journal of occupational and environmental medicine.

[3]  P. Wender.  Attention-deficit hyperactivity disorder in adults. , 1995, The Psychiatric clinics of North America.

[4]  F. Reimherr,et al.  A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. , 2007, The Journal of clinical psychiatry.

[5]  J. Ramos-Quiroga,et al.  Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate , 2008, CNS drugs.

[6]  S. Bálint,et al.  Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. , 2009, The international journal of neuropsychopharmacology.

[7]  E. Nunes,et al.  Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. , 2006, Drug and alcohol dependence.

[8]  S. Faraone,et al.  A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder , 2005, Biological Psychiatry.

[9]  P. Krabbe,et al.  A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. , 2005, Addiction.

[10]  Robert D Gibbons,et al.  3-year follow-up of the NIMH MTA study. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[11]  C. Finley,et al.  Attention deficit disorders in adults. , 1985, Clinical neuropharmacology.

[12]  Joseph Biederman,et al.  Attention Deficit Hyperactivity Disorder in Adults , 2000, JAMA.

[13]  R. Barkley,et al.  Research on Comorbidity, Adaptive Functioning, and Cognitive Impairments in Adults with ADHD: Implications for a Clinical Practice , 2002 .

[14]  I. Maidment.  Efficacy of Stimulants in Adult ADHD , 2003, The Annals of pharmacotherapy.

[15]  J. McGough,et al.  Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder , 2007, Biological Psychiatry.

[16]  George Davey Smith,et al.  Meta-analysis: Beyond the grand mean? , 1997, BMJ.

[17]  S. Pliszka,et al.  Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[18]  B. Toone,et al.  Comorbidity and psychosocial profile of adults with Attention Deficit Hyperactivity Disorder , 2003 .

[19]  A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. , 1985, The American journal of psychiatry.

[20]  M. McDonagh,et al.  Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis , 2008, Psychopharmacology.

[21]  J. Biederman,et al.  Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. , 2004, The international journal of neuropsychopharmacology.

[22]  K. Michalko,et al.  Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults. , 2008, Clinical therapeutics.

[23]  Joseph Biederman,et al.  Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study , 2006, Psychological Medicine.

[24]  J. Mariani,et al.  Treatment strategies for co-occurring ADHD and substance use disorders. , 2007, The American journal on addictions.

[25]  C. Ose,et al.  A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[26]  S. Faraone,et al.  Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. , 1993, The American journal of psychiatry.

[27]  Douglas G. Altman,et al.  Assessing the Quality of Randomised Controlled Trials , 2008 .

[28]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[29]  J. Buitelaar,et al.  A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder , 2008, Biological Psychiatry.

[30]  L. Hechtman,et al.  The Efficacy of 2 Different Dosages of Methylphenidate in Treating Adults with Attention-Deficit Hyperactivity Disorder , 2003, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[31]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[32]  T. Wilens.  Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder , 2012, Drugs.

[33]  F. Castellanos,et al.  Stimulant drugs and ADHD : basic and clinical neuroscience , 2001 .

[34]  J. Swanson.  Compliance with Stimulants for Attention-Deficit/Hyperactivity Disorder , 2003, CNS drugs.

[35]  S. J. Gatley,et al.  Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain , 1997, Psychopharmacology.

[36]  S G Thompson,et al.  Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated , 1994, BMJ.

[37]  T. Banaschewski,et al.  Comparative efficacy of once–a–day extended–release methylphenidate, two–times–daily immediate–release methylphenidate, and placebo in a laboratory school setting , 2004, European Child & Adolescent Psychiatry.

[38]  Douglas G Altman,et al.  Meta-analyses involving cross-over trials: methodological issues. , 2002, International journal of epidemiology.

[39]  J. Markowitz,et al.  Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? , 2008, Journal of clinical psychopharmacology.

[40]  N. Volkow,et al.  Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration , 2004, Synapse.

[41]  Douglas G. Altman,et al.  Systematic reviews in health care : meta-analysis in context , 2008 .

[42]  J. Buitelaar,et al.  Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial , 2004, Psychological Medicine.

[43]  D. Dodd,et al.  An experimental comparison of Pycnogenol® and methylphenidate in adults with Attention-Deficit/ Hyperactivity Disorder (ADHD) , 2002, Journal of attention disorders.

[44]  M. Wasdell,et al.  Effectiveness outcomes in attention-deficit/hyperactivity disorder. , 2006, The Journal of clinical psychiatry.

[45]  S. Faraone,et al.  Comparing the efficacy of medications for ADHD using meta-analysis. , 2006, MedGenMed : Medscape general medicine.

[46]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[47]  S. Faraone,et al.  A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. , 1995, Archives of general psychiatry.

[48]  L. Hechtman,et al.  A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. , 2006, The Journal of clinical psychiatry.

[49]  I. Shoulson,et al.  Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children , 1999, Clinical pharmacology and therapeutics.

[50]  L. Hechtman,et al.  Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. , 2007, The Journal of clinical psychiatry.

[51]  J. Biederman,et al.  A Randomized, Placebo-Controlled Trial of OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder , 2006, Biological Psychiatry.

[52]  S. Evans,et al.  Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. , 2007, Drug and alcohol dependence.

[53]  A. Straughn,et al.  Pharmacokinetics of Methylphenidate After Oral Administration of Two Modified-Release Formulations in Healthy Adults , 2003, Clinical pharmacokinetics.

[54]  L. Boswell,et al.  Methylphenidate effects on symptoms of attention deficit disorder in adults. , 1984, Archives of general psychiatry.

[55]  K. Saules,et al.  Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. , 2002, Experimental and clinical psychopharmacology.

[56]  S. Gupta,et al.  Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. , 2000, Journal of clinical pharmacology.

[57]  T. Spencer,et al.  Efficacy and Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Escalation Study , 2009, Journal of clinical psychopharmacology.

[58]  R. Kilian,et al.  Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder , 2009, Journal of psychopharmacology.

[59]  H. DeCory,et al.  Methylphenidate bioavailability from two extended-release formulations. , 2002, International journal of clinical pharmacology and therapeutics.

[60]  M. Solanto.  Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration , 1998, Behavioural Brain Research.

[61]  S. Faraone,et al.  Meta-Analysis of the Efficacy of Methylphenidate for Treating Adult Attention-Deficit/Hyperactivity Disorder , 2004, Journal of clinical psychopharmacology.

[62]  S. Kuperman,et al.  Bupropion SR vs. Methylphenidate vs. Placebo for Attention Deficit Hyperactivity Disorder in Adults , 2001, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[63]  G. Keating,et al.  Extended- Release Methylphenidate (Ritalin® LA) , 2012, Drugs.

[64]  Suneel K. Gupta,et al.  Single‐ and Multiple‐Dose Pharmacokinetics of an Oral Once‐a‐Day Osmotic Controlled‐Release OROS® (methylphenidate HC1) Formulation , 2000, Journal of clinical pharmacology.